Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer $1.9 Bil. Vicuron Acquisition Culminates Antibiotic Research Deal

Executive Summary

Pfizer's $1.9 bil. purchase of Vicuron marks the culmination of a six-year collaboration between the pharma giant and the biotech company to develop new antibiotic candidates

You may also be interested in...



Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas

As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said

Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas

As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said

Pfizer To Use Cash From Sale Of OTC Unit To J&J For Biotech, Specialty Deals

Pfizer will use the cash gained through the sale of its consumer unit to Johnson & Johnson to make targeted specialty pharma and biotech acquisitions, the firm said following announcement of the deal June 26

Related Content

Topics

UsernamePublicRestriction

Register

PS045965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel